% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • zake1 zake1 Feb 4, 2014 8:21 AM Flag

    INSM to present

    MONMOUTH JUNCTION, NJ -- (Marketwired) -- 02/04/14 -- Insmed Incorporated (NASDAQ: INSM), a biopharmaceutical company focused on developing an inhaled anti-infective to treat patients battling serious lung diseases in orphan indications that are often life-threatening, today announced that members of the Company's executive management team will be presenting at the Leerink Swann Global Healthcare Conference taking place February 12-13, 2014 at the Waldorf Astoria Hotel in New York City.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Leerink "Swann":I posted this a few days ago, timing is everything. Reposting for those who may not have seen.

      Here is their (Joe S) assessment of Insmed last month They have a $22 target currently.

      "Investment Thesis
      • We believe that INSM shares are poised to appreciate as the
      company develops and subsequently commercializes its sole product
      Arikace (inhaled liposomal amikacin) in two attractive orphan
      disease markets: cystic fibrosis (CF) and non-tuberculous
      mycobacteria (NTM).
      • We believe that Arikace presents an attractive clinical profile and is
      differentiated by its unique biochemical capacity to target evasive
      respiratory infections.
      • During 1Q14, we anticipate a readout on Arikace’s safety and
      efficacy in the (potentially pivotal) Phase II TARGET study in
      American NTM patients.
      • We see optionality with INSM shares here after the CLEAR-108
      data, which demonstrated that 1x daily Arikace is non-inferior to 2x
      daily Tobi in cystic fibrosis. If TARGET is a success, INSM shares
      could be worth $30+ on 2025E sales of $1B in NTM/CF. If
      TARGET fails, we model a $340MM worldwide market opportunity
      for Arikace in CF that could create a ~$9 floor value for the stock
      which could be bolstered by Arikace’s potential in other indications
      such as non-CF bronchiectasis.
      • INSM has three Orange Book listable patents including a
      composition of matter patent expiring in 2028 and may be entitled to
      additional market exclusivity under Hatch-Waxman, GAIN act
      legislation, or QIDP for the NTM indication. Our Outperform rating
      reflects our expectation that INSM shares will appreciate as clinical,
      regulatory and commercial catalysts are realized and investors
      augment their view of the company’s potential."

      Sentiment: Buy

    • This would be a good time to announce the timeline for NTM data and possible partnerships. A PR prior to presentation would well serve to create a serious buzz.

      Sentiment: Buy

12.90+0.22(+1.74%)Aug 25 4:00 PMEDT